Boundless Bio Sets Dec 3 Vote on Serapha Reverse Merger, $44-48M Cash Dividend

summarizeSummary

Boundless Bio's amended S-4 sets a December 3, 2026 shareholder vote on its reverse merger with Serapha, with existing holders keeping about 3.8% of the combined company and receiving a roughly $44-48 million pre-closing cash dividend.

check_boxKey Events · M&A and Partnerships · BOLD

• Special Meeting Set for December 3

  Boundless Bio stockholders of record on October 20, 2026 will vote on the Serapha merger, the reverse split, the authorized share increase and related proposals on December 3, 2026.

• Existing Holders Keep 3.8%

  Pre-merger Boundless Bio holders are expected to own about 3.8% of the combined company on a fully diluted basis, with former Serapha holders at about 96.2%.

• $44-48M Pre-Closing Dividend

  Boundless Bio expects to declare a pre-closing cash dividend of approximately $44 million to $48 million, equal to its estimated net cash above zero at closing.

• Serapha Financing Totals ~$230M

  The Serapha pre-closing financing is about $92 million on top of the roughly $138 million Series A, giving the combined company about $230 million at closing.

auto_awesomeAnalysis · BOLD · Life Sciences

Boundless Bio is asking shareholders to approve a reverse merger in which Serapha becomes the surviving business and Boundless Bio holders keep only about 3.8% of the combined company. Before closing, Boundless Bio plans to pay out roughly $44 million to $48 million of its remaining net cash as a pre-closing dividend, so existing holders get cash back plus a small stub of equity in a company now built around Serapha's SERP-01 base-editing therapy for AATD. The vote is set for December 3, 2026, and approval of the share issuance, the reverse split and the authorized share increase are all conditions to closing. The main risk disclosed is the Beam Therapeutics trade secret suit filed September 25, 2026 against Serapha and YolTech over SERP-01, which could delay or block the program.